Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 3065-3067

  Maurin, M ^a   Bryskier, A ^a   Raoult, D ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MACROLIDE; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; THIAMPHENICOL; VANCOMYCIN;

AMOEBA; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDIACEAE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; LEGIONNAIRE DISEASE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARACHLAMYDIA ACANTHAMOEBA; PNEUMONIA; PRIORITY JOURNAL; STRAIN DIFFERENCE; TAXONOMIC IDENTIFICATION;

EID: 0036721151     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.3065-3067.2002     Document Type: Article

References (42)

1. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae
2. Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp.
3. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections
4. Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid
5. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)
6. Community-acquired pneumonia in adults: Guidelines for management
7. In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys
8. Ultrastructural effect of penicillin and cycloheximide on Chlamydia trachomatis strain HAR-13
9. Amoxicillin therapy for Chlamydia trachomatis in pregnancy
10. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro
11. DNA gyrase, topoisomerase IV, and the 4-quinolones
12. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinca pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
13. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms
14. Parachlamydiaceae, potential emerging pathogens
15. In vitro activity of a group of broad-spectrum cephalosporins and other β-lactam antibiotics against Chlamydia trachomatis
16. Neochlamydia hartmannellae gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba Hartmanella vermiformis
17. Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo
18. In vitro drug susceptibility of Chlamydia sp. strain TWAR
19. Chlamydia pneumoniae community-acquired pneumonia: A review of 62 hospitalized adult patients
20. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy
21. Investigation of an outbreak of 'humidifier fever' in a print shop
22. Legionella-like and other amoebal pathogens as agents of community-acquired pneumonia
23. Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci
24. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
25. Why is Chlamydia sensitive to penicillin in the absence of peptidoglycan?
26. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis
27. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
28. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
29. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease
30. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture
31. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
32. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis
33. Isolation of Legionella pneumophila from clinical specimens via amoebae, and the interaction of those and other isolates with amoebae
34. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
35. In-vitro activity of azithromycin against Chlamydia trachomatis
36. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis
37. A randomized, prospective trial comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy
38. Effect of penicillin on the multiplication of meningopneumonitis organisms (Chlamydia psittaci)
39. Use of gentamicin in the isolation of subgroup A Chlamydia
40. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan